Agenovir Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Agenovir General Information

Description

Developer of novel therapeutics designed to address diseases associated with or caused by, latent or persistent viral reservoirs. The company's novel therapeutics specialize in developing a novel class of nuclease-based anti-viral therapeutics to eliminate pathogenic viral genomes, enabling healthcare providers to treat their patients suffering from devastating and persistent viral infection.

Contact Information

Website
www.agenovir.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 7000 Shoreline Court
  • Suite 320
  • South San Francisco, CA 94080
  • United States
Primary Industry
Biotechnology
Acquirer
Vir
Vertical(s)
Life Sciences
Corporate Office
  • 7000 Shoreline Court
  • Suite 320
  • South San Francisco, CA 94080
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Agenovir Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 09-May-2018 000.00 Completed Generating Revenue
3. Early Stage VC (Series A) 17-May-2016 000.00 000.00 000.00 Completed Generating Revenue
2. Grant 01-Jan-2016 $149K Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Agenovir’s complete valuation and funding history, request access »

Agenovir Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view Agenovir’s complete cap table history, request access »

Agenovir Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutics designed to address diseases associated with or caused by, latent or persistent viral re
Biotechnology
South San Francisco, CA
000.00
000000&0 000.00

000000

uip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate
0000 000000000
South San Francisco, CA
00 As of 0000
00000
00000 0000-00-00
00000000000 00000

000000

or in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariat
0000 000000000
Pittsburgh, PA
00 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Agenovir Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AsherBio Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
CytoAgents Venture Capital-Backed Pittsburgh, PA 00 000.00 000000000 000.00
TScan Therapeutics Formerly VC-backed Waltham, MA 000 00000 00000000 00000
Intellia Therapeutics Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
Celldex Therapeutics Formerly VC-backed Hampton, NJ 000 00.000 00000000 00.000
You’re viewing 5 of 7 competitors. Get the full list »

Agenovir Patents

  • 49

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Agenovir Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3601568-A1 Antiviral therapeutic Inactive 31-Mar-2017 00000000000
AU-2017223964-A1 Viral and oncoviral nuclease treatment Inactive 25-Feb-2016 0000000000
US-20170247703-A1 Antiviral nuclease methods Inactive 25-Feb-2016 00000000000
EP-3420077-A1 Viral and oncoviral nuclease treatment Inactive 25-Feb-2016 0000000000
US-20170246260-A1 Modified antiviral nuclease Inactive 25-Feb-2016 A61K38/465
To view Agenovir’s complete patent history, request access »

Agenovir Executive Team (5)

Name Title Board Seat
Dirk Thye MD Chief Executive Officer, President and Board Member
Bolyn Hubby Ph.D Chief Scientific Officer
Angela Wu Co-Founder & Advisor
You’re viewing 3 of 5 executive team members. Get the full list »

Agenovir Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Celgene Corporation Minority 000 0000 000000 0
DCVC Venture Capital Minority 000 0000 000000 0
Lightspeed Management Company Venture Capital Minority 000 0000 000000 0
QB3 Accelerator/Incubator 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view Agenovir’s complete investors history, request access »

Ready to get started?

Request a free trial

Agenovir FAQs

  • When was Agenovir founded?

    Agenovir was founded in 2014.

  • Who is the founder of Agenovir?

    Jianbin Wang Ph.D, Angela Wu, and Stephen Quake Ph.D are the founders of Agenovir.

  • Who is the CEO of Agenovir?

    Dirk Thye MD is the CEO of Agenovir.

  • Where is Agenovir headquartered?

    Agenovir is headquartered in South San Francisco, CA.

  • What industry is Agenovir in?

    Agenovir’s primary industry is Biotechnology.

  • Is Agenovir a private or public company?

    Agenovir is a Private company.

  • What is Agenovir’s current revenue?

    The current revenue for Agenovir is 00000.

  • How much funding has Agenovir raised over time?

    Agenovir has raised $10.6M.

  • Who are Agenovir’s investors?

    Celgene, DCVC, Lightspeed Management Company, QB3, and U.S. Department of Health and Human Services have invested in Agenovir.

  • Who are Agenovir’s competitors?

    AsherBio, CytoAgents, TScan Therapeutics, Intellia Therapeutics, and Celldex Therapeutics are some of the 7 competitors of Agenovir.

  • When was Agenovir acquired?

    Agenovir was acquired on 09-May-2018.

  • Who acquired Agenovir?

    Agenovir was acquired by Vir.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »